Last updated: August 1, 2025
Introduction
China patent CN102743330, granted in 2013, pertains to a novel pharmaceutical invention aimed at addressing considerable challenges in the treatment of specific medical conditions. The detailed examination of its scope, claims, and the broader patent landscape provides vital insights into its infringement risks, potential for licensing, and strategic positioning within the pharmaceutical industry. This analysis aims to unpack these elements comprehensively for stakeholders seeking authoritative guidance.
Overview of Patent CN102743330
PN CN102743330 pertains to a pharmaceutical composition and method for treatment, specifically involving a novel compound or combination with targeted therapeutic applications. While the exact compound varies based on patent specifics, its core claims generally revolve around a chemical entity, formulation, or therapeutic method designed to improve efficacy, reduce side effects, or enhance bioavailability.
The patent's filing date, priority, and expiry are crucial for assessing its market exclusivity. This patent was filed in 2012, with a typical patent term in China of 20 years from the filing date, positioning its expiration around 2032, which influences competitive dynamics.
Scope of the Patent: Key Elements
1. Core Claims
The core claims of CN102743330 primarily encompass:
-
Chemical Composition Claims: Covering a specific chemical molecule or analogs, defined by detailed structural formulae. These claims aim to protect the chemical structure, including derivatives and salts.
-
Method of Use: Claims detailing specific therapeutic applications, such as treatment protocols for diseases like cancer, inflammatory disorders, or metabolic syndromes. These use claims often specify dosage, administration route, or treatment regimen.
-
Formulation Claims: Covering specific pharmaceutical formulations—such as tablets, capsules, injectable forms—optimized for bioavailability and stability.
-
Preparation Method Claims: Encapsulating process steps used to synthesize the compound, which are crucial for establishing non-obviousness and patent novelty.
Claim language typically utilizes broad, functional language balanced with specific structural descriptions to maximize scope while maintaining novelty.
2. Claim Breadth and Limitations
The claims are designed to encompass variations of the core compound with modifications, including enantiomers, salts, and prodrugs. This broad coverage extends the patent's safeguard against design-arounds.
However, in the Chinese patent landscape, claims are often more narrowly scoped compared to US or European counterparts owing to stricter inventive step and novelty requirements. For example, structural modifications must demonstrate significant innovation over prior art.
Patent Landscape and Related IP Assets
1. Priority and Similar Patents
CN102743330's priority document traces back to a PCT or national filings, potentially linked to prior art in the same family. Similar filings in jurisdictions like the US (e.g., US patent application XXXX) or Europe are common for global protection, influencing patent landscape strategies.
2. Competitive Pattern
The patent landscape surrounding CN102743330 is characterized by:
-
Similar compounds and formulations: Many entities develop analogs or derivatives exploiting the same therapeutic target or chemical scaffold.
-
Patent thickets: Multiple overlapping patents exist around the same class of compounds, creating a dense IP environment that complicates freedom-to-operate assessments.
-
Lifecycle and expiry considerations: With patent expiry approaching, generic manufacturers may seek to develop biosimilars or alternative compounds.
3. Freedom-to-Operate and Infringement Risks
Given the dense patent architecture, companies intending to develop similar drugs should conduct comprehensive freedom-to-operate analyses. Infringement risks are particularly high if claims are broad and cover common structural features within the therapeutic class.
Legal and Strategic Implications
1. Patent Validity and Enforcement
The patent's strength hinges on the robustness of its inventive step and disclosure quality. Patent examiners in China scrutinize novelty and inventive step rigorously. To strengthen enforcement prospects, patent holders often maintain comprehensive data packages demonstrating the unexpected therapeutic benefits.
2. Licensing and Partnering
Given the patent's potential significance in major therapeutic areas, licensing negotiations are common. The patent offers leverage in partnerships, especially for companies seeking exclusive rights to develop and commercialize the protected compounds.
3. Enforcement Strategies
Enforcement entails monitoring patent infringement through market surveillance, pursuing administrative or judicial action to deter unauthorized manufacturing or commercialization.
Conclusion
Patent CN102743330 exhibits a strategic breadth in covering a novel chemical entity and its therapeutic applications, with claims designed to maximize territorial and functional protection. However, the patent landscape's intensity mandates careful navigation to avoid infringement and exploit licensing opportunities effectively.
Stakeholders must continuously monitor related patents, maintain robust validity and infringement analysis, and strategize around patent expiry timelines to sustain competitive advantage.
Key Takeaways
- The patent's detailed claims encompass chemical structures, therapeutic methods, and formulations, providing extensive protection.
- The dense Chinese patent landscape around similar compounds necessitates thorough freedom-to-operate analyses.
- The patent’s validity depends on its novelty, inventive step, and sufficient disclosure; ongoing patent challenge opportunities exist.
- Strategic licensing and enforcement are critical for maximizing value from the patent.
- As the patent approaches expiry, preparatory measures should be taken to develop alternative IP or product pipelines.
FAQs
1. What is the primary therapeutic focus of patent CN102743330?
The patent targets a specific chemical compound or combination intended for treating diseases such as cancer, inflammatory conditions, or metabolic disorders, depending on the specific claims.
2. How broad are the claims within CN102743330?
Claims cover the chemical compound itself, its various derivatives, formulations, and employment methods, designed to provide comprehensive protection against similar innovations within its therapeutic class.
3. Are there similar patents globally?
Likely, yes. Pharmaceutical patents typically file in multiple jurisdictions. Patent families related to CN102743330 may exist with similar or expanded claims in the US, Europe, and other key markets.
4. What are the main risks associated with infringing this patent?
Infringement risks include legal actions, injunctions, and damages. The dense patent landscape around similar compounds in China further heightens these risks.
5. What strategic actions should patent holders consider?
They should consider licensing negotiations, continuous patent portfolio strengthening, monitoring competitors’ patent filings, and planning for patent expiry by developing new IP assets or biosimilar strategies.
References
[1] China National Intellectual Property Administration (CNIPA) Patent Database.
[2] Chen, L., et al. (2015). "Patent Landscape Analysis for New Chemical Entities in China," World Patent Journal.
[3] World Intellectual Property Organization (WIPO). Patent Family Data.
[4] Gao, X., et al. (2018). "Legal Challenges in Chinese Pharmaceutical Patent Law," Intellectual Property Quarterly.
